InsiderClue
← All stocks

Climb Bio, Inc.

CLYM Net buying
CIK 0001768446 #2557 in the set updated 19 Sep 2026
Bought (12 mo)
$779.63K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$2.65M
$2.65M on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 6 sales
Net
−$1.87M
+$779.63K against sales at will

By person

4 insiders · 9 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Thomas Stephen Basil
Director
—
$2.25M (5) scheduled
−$2.25M
467,969
0.8148%
$6.40M
−9.5%
RA CAPITAL MANAGEMENT, L.P. entity
Director
$779.63K (3)
—
+$779.63K
3,403,429
5.93%
$46.52M
−85.5%
Brennan Aoife
President and CEO
—
$406.98K (1) scheduled
−$406.98K
87,731
0.1527%
$1.20M
+4,910%
Pimblett Emily
SVP, Finance & CAO
—
—
—
18,888
0.0329%
$258.16K
+115.7%

Individual transactions

9
Insider
Date
Role
Action
Shares
Price
Amount
Thomas Stephen Basil
15 Sep 2026
Director
Sold on a plan
100,000
$13.67
$1.37M
Brennan Aoife
29 Jun 2026
President and CEO
Sold on a plan
30,902
$13.17
$406.98K
Thomas Stephen Basil
26 Feb 2026
Director
Sold on a plan
16,313
$7.01
$114.29K
Thomas Stephen Basil
25 Feb 2026
Director
Sold on a plan
33,687
$7.00
$235.96K
Thomas Stephen Basil
13 Feb 2026
Director
Sold on a plan
10,000
$5.81
$58.14K
Thomas Stephen Basil
12 Feb 2026
Director
Sold on a plan
90,000
$5.23
$470.99K
RA CAPITAL MANAGEMENT, L.P.
5 Jan 2026
Director
Buy indirect
7,111
$3.50
$24.89K
RA CAPITAL MANAGEMENT, L.P.
12 Dec 2025
Director
Buy indirect
101,462
$2.86
$290.18K
RA CAPITAL MANAGEMENT, L.P.
11 Dec 2025
Director
Buy indirect
213,099
$2.18
$464.56K

What was left out

Form 4 filings counted 21
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 5
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 20,508,750
History held since 11 Aug 2021